189 related articles for article (PubMed ID: 24460291)
1. MCPH1 Protein Expression in Normal and Neoplastic Lung Tissues.
Zhang J; Wu XB; Fan JJ; Mai L; Cai W; Li D; Yuan CF; Bu YQ; Song FZ
Asian Pac J Cancer Prev; 2013; 14(12):7295-300. PubMed ID: 24460291
[TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
[TBL] [Abstract][Full Text] [Related]
3. Expression of tumor necrosis factor receptor-associated factor 6 in lung cancer tissues.
Zhang XL; Dang YW; Li P; Rong MH; Hou XX; Luo DZ; Chen G
Asian Pac J Cancer Prev; 2014; 15(24):10591-6. PubMed ID: 25605144
[TBL] [Abstract][Full Text] [Related]
4. Expression of high mobility group box - B1 (HMGB-1) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer (NSCLC).
Wang JL; Wu DW; Cheng ZZ; Han WZ; Xu SW; Sun NN
Asian Pac J Cancer Prev; 2014; 15(12):4865-9. PubMed ID: 24998555
[TBL] [Abstract][Full Text] [Related]
5. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of inflammasomes in lung cancer cell lines and tissues.
Kong H; Wang Y; Zeng X; Wang Z; Wang H; Xie W
Tumour Biol; 2015 Sep; 36(10):7501-13. PubMed ID: 25910707
[TBL] [Abstract][Full Text] [Related]
7. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
8. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Micke P; Mattsson JS; Djureinovic D; Nodin B; Jirström K; Tran L; Jönsson P; Planck M; Botling J; Brunnström H
J Thorac Oncol; 2016 Jun; 11(6):862-72. PubMed ID: 26872818
[TBL] [Abstract][Full Text] [Related]
9. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
Gürel D; Kargı A; Karaman I; Onen A; Unlü M
Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
[TBL] [Abstract][Full Text] [Related]
10. FBXO25 promotes cell proliferation, invasion, and migration of NSCLC.
Jiang GY; Zhang XP; Wang L; Lin XY; Yu JH; Wang EH; Zhang Y
Tumour Biol; 2016 Oct; 37(10):14311-14319. PubMed ID: 27596142
[TBL] [Abstract][Full Text] [Related]
11. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
[TBL] [Abstract][Full Text] [Related]
16. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
17. Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer.
Fan C; Yu J; Liu Y; Xu H; Wang E
Pathol Oncol Res; 2012 Jul; 18(3):549-56. PubMed ID: 20853080
[TBL] [Abstract][Full Text] [Related]
18. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
19. Association of FOXP3 expression with non-small cell lung cancer.
Dimitrakopoulos FI; Papadaki H; Antonacopoulou AG; Kottorou A; Gotsis AD; Scopa C; Kalofonos HP; Mouzaki A
Anticancer Res; 2011 May; 31(5):1677-83. PubMed ID: 21617226
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
